TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38896381

Group type: EXPERIMENTAL
Intervention: apremilast 30 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 38896380

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg/day
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg (dose increase from 100 mg)
Number of subjects: 453
Study: 38896403

Group type: EXPERIMENTAL
Intervention: Sonidegib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protocol modifications (treatment interruptions and dose reductions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic and pharmacologic interventions
Number of subjects: 0
Study: 38896452

Group type: EXPERIMENTAL
Intervention: webMFT
Number of subjects: 56

Group type: COMPARATOR
Intervention: MVPA tracking (control)
Number of subjects: 56
Study: 38896602

Group type: EXPERIMENTAL
Intervention: Delgocitinib ointment
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Topical JAK inhibition
Number of subjects: 11

Group type: COMPARATOR
Intervention: Afatinib (EGFR inhibitor)
Number of subjects: 11
Study: 38896810

Group type: EXPERIMENTAL
Intervention: RT-QuIC seeding activity in CSF
Number of subjects: 41

Group type: COMPARATOR
Intervention: RT-QuIC negative
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Neurodegenerative and neuroinflammatory markers
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CSF PrP levels
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CSF prion seeding activity
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Neuronal damage and neuroinflammation markers
Number of subjects: 41
Study: 38896837

Group type: EXPERIMENTAL
Intervention: Multi-Aid-Package (mHealth intervention)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 439
Study: 38896851

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 586

Group type: COMPARATOR
Intervention: Usual obesity care
Number of subjects: 586
Study: 38896853

Group type: EXPERIMENTAL
Intervention: Deep learning computed risk score (DLCR) model
Number of subjects: 707

Group type: COMPARATOR
Intervention: UISS/Leibovich score/Rad-Score
Number of subjects: 707
Study: 38897097

Group type: EXPERIMENTAL
Intervention: Oral nomegestrol acetate/estradiol 1.5 mg/2.5 mg/day for 14 days (random start)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no pharmaceutical treatment)
Number of subjects: 80
Study: 38897103

Group type: EXPERIMENTAL
Intervention: Hand-foot exercises program (3 sessions a day, 3 days a week for 8 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (routine treatment and care)
Number of subjects: 39
Study: 38897136

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 325
Study: 38897155

Group type: EXPERIMENTAL
Intervention: Various treatments (248 treatments administered)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Younger age at disease onset
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Short delay from onset of relapse to treatment initiation
Number of subjects: 120
Study: 38897584

Group type: EXPERIMENTAL
Intervention: Mild hyperthermia with MR-guided high intensity focused ultrasound (MR-HIFU) combined with concurrent chemoradiation (30.6 Gy in 1.8 Gy fractions with capecitabine)
Number of subjects: 6
Study: 38897621

Group type: EXPERIMENTAL
Intervention: Complete ANS exposure
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Partial ANS exposure
Number of subjects: 725

Group type: COMPARATOR
Intervention: No ANS exposure
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Partial and complete ANS exposure
Number of subjects: 725
Study: 38898018

Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg on day 1 plus modified TPF (docetaxel 75 mg/m2) for three cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus modified TPF
Number of subjects: 0
Study: 38898120

Group type: EXPERIMENTAL
Intervention: Entrectinib 600 mg daily
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Entrectinib (integrated analysis)
Number of subjects: 55
Study: 38898468

Group type: EXPERIMENTAL
Intervention: Sprint athletes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Endurance athletes
Number of subjects: 24
Study: 38898522

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham-taVNS
Number of subjects: 42
Study: 38898537

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention for Trauma in Schools (CBITS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Enhanced treatment-as-usual condition (TAU +)
Number of subjects: 90
Study: 38898573

Group type: EXPERIMENTAL
Intervention: Cardiac shockwave therapy (SWT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 63
Study: 38898664

Group type: EXPERIMENTAL
Intervention: Nutritional impairment (defined as MNA-SF ≤11)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: MNA-SF ≤11
Number of subjects: 541
Study: 38898892

Group type: EXPERIMENTAL
Intervention: Personal aptitudes and personality traits
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Social determinants of health and interpersonal relationships
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Psychological capacity, physical capacity, physical opportunity, social opportunity, reflective motivation, automatic motivation
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Need for control, overthinking, ambivalence
Number of subjects: 156
Study: 38899114

Group type: EXPERIMENTAL
Intervention: da Vinci SP system for anatomical lung resection
Number of subjects: 35
Study: 38899206

Group type: EXPERIMENTAL
Intervention: Inhibition of interleukin-33 (IL-33) signaling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocking the IL-33 pathway
Number of subjects: 0
Study: 38899545

Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 5752

Group type: COMPARATOR
Intervention: Haemodialysis (HD)
Number of subjects: 5752
Study: 38899599

Group type: EXPERIMENTAL
Intervention: Steps 1-2 (non-surgical) of periodontal therapy (test group; n=37)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No treatment (control group; n=37)
Number of subjects: 74
Study: 38899693

Group type: EXPERIMENTAL
Intervention: ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) administered every 21 days for six cycles
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide)
Number of subjects: 60
Study: 38899695

Group type: EXPERIMENTAL
Intervention: CM313 (anti-CD38 monoclonal antibody) administered intravenously at a dose of 16 mg/kg every week for 8 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CM313 (anti-CD38 monoclonal antibody)
Number of subjects: 22
Study: 38899716

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus Trametinib
Number of subjects: 870

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 870
Study: 38899776

Group type: EXPERIMENTAL
Intervention: Gamified delivery group (on-demand exercise videos and weekly exercise duration leaderboards)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Packet group (take-home packet)
Number of subjects: 40
Study: 38899824

Group type: EXPERIMENTAL
Intervention: Tub bathing (experimental group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No tub bathing (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tunnel-experimental group (tub bathing with tunnel phototherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tunnel control group (no tub bathing with tunnel phototherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Light-emitting diode-experimental group (tub bathing with LED phototherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Light-emitting diode control group (no tub bathing with LED phototherapy)
Number of subjects: 0
Study: 38900037

Group type: EXPERIMENTAL
Intervention: Ibrutinib in combination with R-GemOx (rituximab, gemcitabine, and oxaliplatin)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ibrutinib maintenance
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ibrutinib in combination with R-GemOx
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 64
Study: 38900182

Group type: EXPERIMENTAL
Intervention: Resiliency education
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Cautionary education
Number of subjects: 903

Group type: COMPARATOR
Intervention: Control group (standardized Army deadlift education only)
Number of subjects: 903
Study: 38900225

Group type: EXPERIMENTAL
Intervention: CPAP + 4
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham-CPAP (Control)
Number of subjects: 46
Study: 38900283

Group type: EXPERIMENTAL
Intervention: Standardised qualitative assessment
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: GWR-8
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: GWR-4
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Automated GWR
Number of subjects: 140
Study: 38900305

Group type: EXPERIMENTAL
Intervention: Enhanced recovery programs (ERP)
Number of subjects: 50
Study: 38900416

Group type: EXPERIMENTAL
Intervention: FCH PET/CT (FCH1)
Number of subjects: 57

Group type: COMPARATOR
Intervention: MIBI SPECT/CT (MIBI1)
Number of subjects: 57
Study: 38900426

Group type: EXPERIMENTAL
Intervention: Vegetable gardening intervention
Number of subjects: 381

Group type: COMPARATOR
Intervention: Waitlisted control
Number of subjects: 381
Study: 38900435

Group type: EXPERIMENTAL
Intervention: SOR-TACE (sorafenib 400 mg twice daily plus on-demand TACE)
Number of subjects: 162

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: SOR-TACE
Number of subjects: 162
Study: 38900452

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX (6 cycles preoperative and 6 cycles adjuvant)
Number of subjects: 46
Study: 38900484

Group type: EXPERIMENTAL
Intervention: Intravitreous lampalizumab, 0.1 mL, every 4 weeks
Number of subjects: 1851

Group type: EXPERIMENTAL
Intervention: Intravitreous lampalizumab, 0.1 mL, every 6 weeks
Number of subjects: 1851

Group type: COMPARATOR
Intervention: Sham procedure every 4 weeks
Number of subjects: 1851

Group type: COMPARATOR
Intervention: Sham procedure every 6 weeks
Number of subjects: 1851
Study: 38900490

Group type: EXPERIMENTAL
Intervention: CRDS cases
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control patients with suspected supraventricular tachycardia
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control patients (UCA and CPVT)
Number of subjects: 68
Study: 38900505

Group type: EXPERIMENTAL
Intervention: Polar H10 chest monitor
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fitbit Inspire HR
Number of subjects: 14
Study: 38900513

Group type: EXPERIMENTAL
Intervention: Baseline active coping
Number of subjects: 115
Study: 38900565

Group type: EXPERIMENTAL
Intervention: Chronic stress exposure (including stress from COVID-19)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Caregiver-child relationship quality, caregiver education, and caregiver self-regulation
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Remote data collection methods including questionnaires and measures
Number of subjects: 359
Study: 38900570

Group type: EXPERIMENTAL
Intervention: Psychological distress in caregivers (measured by various instruments)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Spinal ALS patients
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Male ALS patients with preserved cognition
Number of subjects: 51
Study: 38900700

Group type: EXPERIMENTAL
Intervention: Facilitated diabetes management game
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group playing the game alone
Number of subjects: 48
Study: 38900773

Group type: EXPERIMENTAL
Intervention: Fermented high zinc agronomically biofortified wheat flour flatbread
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Unfermented high zinc agronomically biofortified wheat flour flatbread
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Post-harvest zinc-fortified wheat flour flatbread
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Low zinc conventional whole wheat flour flatbread
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: All interventions (fermented, unfermented, post-harvest zinc-fortified)
Number of subjects: 1000
Study: 38900984

Group type: EXPERIMENTAL
Intervention: SHR-A1811 (1.0 to 8.0 mg/kg, IV, once every 3 weeks)
Number of subjects: 307
Study: 38900987

Group type: EXPERIMENTAL
Intervention: Fianlimab 1,600 mg and cemiplimab 350 mg intravenously once every 3 weeks for up to 51 weeks (with optional additional 51 weeks if clinically indicated)
Number of subjects: 118
Study: 38901008

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine, mean dose at week 145: 40.4 mg/d for psychotic disorders, 38.5 mg/d for mood and other disorders, 39.9 mg/d for those receiving DRAs, 38.5 mg/d for those not receiving DRAs.
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Deutetrabenazine
Number of subjects: 343
Study: 38901021

Group type: EXPERIMENTAL
Intervention: Predictive risk models (PRMs) for CRS
Number of subjects: 54
Study: 38901084

Group type: COMPARATOR
Intervention: Methotrexate (n = 43)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 5-day Letrozole (n = 24)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 10-day Letrozole (n = 21)
Number of subjects: 88
Study: 38901179

Group type: EXPERIMENTAL
Intervention: KEβHB-supplemented beverage
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 18
Study: 38901293

Group type: EXPERIMENTAL
Intervention: Subcutaneous drain insertion
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control (no subcutaneous drain)
Number of subjects: 162
Study: 38901299

Group type: EXPERIMENTAL
Intervention: Preference-based participation in orthopaedic care
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Reciprocal communication, opportunities for partaking in planning, and learning how to manage symptoms/issues
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: Hip fracture surgery
Number of subjects: 458
Study: 38901423

Group type: EXPERIMENTAL
Intervention: 5:2 intermittent fasting
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy living diet
Number of subjects: 40
Study: 38901425

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI+BEV
Number of subjects: 103

Group type: COMPARATOR
Intervention: CAPOXIRI+BEV
Number of subjects: 103
Study: 38901444

Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide
Number of subjects: 124
Study: 38901489

Group type: EXPERIMENTAL
Intervention: BIS-guided deep sedation (BIS range, 40-60)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Clinical assessment (CA)
Number of subjects: 99
Study: 38901559

Group type: EXPERIMENTAL
Intervention: Insulin regulation in men with NASH
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Insulin regulation in men with simple steatosis
Number of subjects: 17
Study: 38901633

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Mosunetuzumab
Number of subjects: 127
Study: 38901636

Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 156

Group type: COMPARATOR
Intervention: BPI
Number of subjects: 156
Study: 38901823

Group type: EXPERIMENTAL
Intervention: Cantilevered zirconia RBFPDs
Number of subjects: 36
Study: 38901858

Group type: EXPERIMENTAL
Intervention: JADE-PRISM group (multicomponent care model with specialist-led team-based management)
Number of subjects: 884

Group type: COMPARATOR
Intervention: Usual care (JADE-only)
Number of subjects: 884
Study: 38901877

Group type: EXPERIMENTAL
Intervention: Female patients with asthma
Number of subjects: 773

Group type: COMPARATOR
Intervention: Male patients with asthma
Number of subjects: 773
Study: 38901942

Group type: EXPERIMENTAL
Intervention: Family caregivers' nutritional status
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CRs' MNA scores
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CRs' number of comorbidities
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CRs' P-hs-CRP levels
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: CRs' hand grip strength
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: FCs' MNA scores
Number of subjects: 120
Study: 38901946

Group type: EXPERIMENTAL
Intervention: Daytime infusions of HPN
Number of subjects: 9

Group type: COMPARATOR
Intervention: Overnight infusions of HPN
Number of subjects: 9
Study: 38901960

Group type: EXPERIMENTAL
Intervention: ILM peeling
Number of subjects: 213

Group type: COMPARATOR
Intervention: No ILM peeling
Number of subjects: 213
Study: 38902005

Group type: EXPERIMENTAL
Intervention: LEV 20 or 40 mg/kg bolus followed by 5 or 10 mg/kg maintenance dose daily (NEOLEV1)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 40 mg/kg intravenous LEV load, followed by 10 mg/kg doses 8 hourly (NEOLEV2)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Further 20 mg/kg intravenous load if seizures persisted (NEOLEV2)
Number of subjects: 49

Group type: COMPARATOR
Intervention: PHB if seizures persisted after LEV (NEOLEV2)
Number of subjects: 49
Study: 38902383

Group type: EXPERIMENTAL
Intervention: 3-day oseltamivir prophylaxis
Number of subjects: 59

Group type: COMPARATOR
Intervention: 7-day oseltamivir prophylaxis
Number of subjects: 59
Study: 38902464

Group type: EXPERIMENTAL
Intervention: Measurements of waist circumference (WC) at three distinct locations along the abdomen
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Systolic (SBP) and diastolic blood pressure (DBP) measurements
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Traditional metabolic syndrome (MetS) risk factors
Number of subjects: 139
Study: 38902487

Group type: EXPERIMENTAL
Intervention: Yoga intervention for patient-partner dyads over 12 weeks
Number of subjects: 23
Study: 38902546

Group type: EXPERIMENTAL
Intervention: UB-312 (300/100/100 μg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: UB-312 (300/300/300 μg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: UB-312
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 38902571

Group type: EXPERIMENTAL
Intervention: ALZ-801 265 mg tablet taken twice daily (after 2 weeks once daily)
Number of subjects: 84
Study: 38902572

Group type: EXPERIMENTAL
Intervention: ALZ-801 265 mg two times daily (BID)
Number of subjects: 83
Study: 38902616

Group type: EXPERIMENTAL
Intervention: Digital physical activity intervention with social support features
Number of subjects: 181

Group type: COMPARATOR
Intervention: Tablet-based educational control
Number of subjects: 181
Study: 38902652

Group type: EXPERIMENTAL
Intervention: IMCY-0098
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38902668

Group type: EXPERIMENTAL
Intervention: CASC score
Number of subjects: 796

Group type: COMPARATOR
Intervention: qSOFA score
Number of subjects: 796

Group type: COMPARATOR
Intervention: NEWS-2 score
Number of subjects: 796
Study: 38902691

Group type: EXPERIMENTAL
Intervention: Edaravone dexborneol (37.5 mg/12 hours, IV)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (no edaravone dexborneol treatment)
Number of subjects: 85
Study: 38902731

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control strategy (target BP < 130/80 mmHg)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control strategy
Number of subjects: 1000
Study: 38902742

Group type: EXPERIMENTAL
Intervention: Perceval PLUS sutureless valve
Number of subjects: 328
Study: 38902747

Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel administration
Number of subjects: 988
Study: 38902790

Group type: EXPERIMENTAL
Intervention: Male Wolbachia-infected Aedes aegypti deployments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study: 38902794

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 38902811

Group type: EXPERIMENTAL
Intervention: Voluntary isocapnic hyperpnoea (VIH) recovery protocol performed 20 min after exercise
Number of subjects: 39

Group type: COMPARATOR
Intervention: Passive recovery only
Number of subjects: 39
Study: 38902836

Group type: EXPERIMENTAL
Intervention: Recurrence-focused surveillance including clinical evaluation, serum cancer antigen (CA) 19-9 testing, and contrast-enhanced CT of chest and abdomen every three months for the first 2 years after surgery.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-standardized clinical follow-up consisting of clinical follow-up with imaging and serum tumor marker testing only in case of onset of symptoms, according to local practice.
Number of subjects: 0
Study: 38902840

Group type: EXPERIMENTAL
Intervention: Low anterior resection syndrome score (LARS) assessment after colon resection
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Assessment of specific bowel symptoms and patient-reported distress
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Assessment of loose stools occurrence after right-sided resection
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Correlation analysis of incontinence and loose stools with distress
Number of subjects: 1221
Study: 38902846

Group type: EXPERIMENTAL
Intervention: InterCARE care model integrating HIV and hypertension care through provider training, adapted electronic health record, and treatment partners (peer support)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: InterCARE care model
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Integration of hypertension services into HIV clinics
Number of subjects: 290
Study: 38902860

Group type: EXPERIMENTAL
Intervention: Single dose of mRNA-1273 (100 μg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Double dose of mRNA-1273 (2×100 μg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Single dose of Ad26.COV2.S (adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Continuation of mycophenolate mofetil/mycophenolic acid after vaccination
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Discontinuation of mycophenolate mofetil/mycophenolic acid after vaccination
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2 primary mRNA-1273 vaccinations (reference group)
Number of subjects: 100